Dublin, Feb. 02, 2017 -- Research and Markets has announced the addition of the "Closed Drug Transfer Systems to 2022" report to their offering.
The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers.
Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues. Studies of nurses who work with cytotoxic drugs on a regular basis have found a statistically higher rate of spontaneous abortion. Several companies are responding to this unmet need by commercializing devices for closed transfer of these drugs. As the market evolves and user acceptance increases, so too will the impact of these products on oncology therapy protocols and drug delivery
Highlights
- Analyzes the impact of drug toxicity and safety factors on therapeutic oncology market segments, market dynamics and market demographics
- Provides detailed analysis of closed drug transfer products for the handing of cytotoxic drugs
- Analyzes demand drivers and competitive factors influencing closed drug transfer adoption
- Charts product data and provides forecasts to 2022
- Profiles closed drug transfer device participants, their product development activities, business strategies, and corporate alliances and affiliations
Key Topics Covered:
1. Executive Summary
2. Cytotoxic Drug Therapeutics Market Dynamics
- Therapeutic Trends and Issues
- The Administration of injectable/Infusible Antineoplastics
- Drug Packaging and Administration Technology
- Closed Drug Transfer Market Drivers
- Competitive Landscape
- Risk Factors
3. Closed Drug Transfer Design Factors
- Key System Design Elements
- Human Engineering/Ergonomics
- Material Selection Issues
- Drug Reconstitution and Dilution
- Oncology Therapeutics Medication Safety
- Oncology Drug Administration and Dosing
- Drug-Specific Dosing Modification and Individualized Dosing
4. Closed Drug Transfer - Commercial Device Assessments
5. Market Factors
6. Regulatory Issues
- Caregiver Compliance
- Level of Complexity and Ease of Use
- Healthcare Economics
- Business Models and Strategies
7. Market Assessments and Forecasts
8. North America
- Europe
- Asia
- Other Geographic Markets
9.Closed Drug Transfer - Market Participant Profiles
For more information about this report visit http://www.researchandmarkets.com/research/fdrxr6/closed_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery


Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 



